Novel ubiquitin-derived high affinity binding proteins with tumor targeting properties

Journal of Biological Chemistry

Volumn 289, Issue 12, 2014, Pages 8493-8507

  Lorey, Susan ^a   Fiedler, Erik ^a   Kunert, Anja ^a   Nerkamp, Jörg ^a   Lange, Christian ^a   Fiedler, Markus ^a   Bosse Doenecke, Eva ^a   Meysing, Maren ^a   Gloser, Manja ^a   Rundfeldt, Chris ^a   Rauchhaus, Una ^a   Hänssgen, Ilka ^a   Göttler, Thomas ^a   Steuernagel, Arnd ^a   Fiedler, Ulrike ^a   Haupts, Ulrich ^a  

^a Scil Proteins GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HISTOLOGY; MOLECULES; SCAFFOLDS (BIOLOGY); TUMORS;

BINDING MOLECULES; BINDING PROTEINS; BIOCHEMICAL PROPERTIES; HIGH AFFINITY BINDING; HIGH-AFFINITY BINDERS; MOLECULAR COMPLEXITY; SYSTEMIC CIRCULATION; TUMOR ACCUMULATION;

PROTEINS;

BINDING PROTEIN; FIBRONECTIN; UBIQUITIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; BIOACCUMULATION; CONTROLLED STUDY; FEMALE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PHAGE DISPLAY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; THERMODYNAMICS; THERMOSTABILITY;

AFFILIN; BIODISTRIBUTION; HALF-LIFE EXTENSION; PHAGE DISPLAY; PROTEIN ENGINEERING; SCAFFOLD PROTEINS; TUMOR MARKER; UBIQUITIN;

ANIMALS; CELL LINE; FIBRONECTINS; HUMANS; MICE; MODELS, MOLECULAR; NEOPLASMS; PEPTIDE LIBRARY; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN STRUCTURE, TERTIARY; UBIQUITIN;

EID: 84897014099     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.519884     Document Type: Article

References (65)

1. Reichert, J. M. (2012) Marketed therapeutic antibodies compendium. mAbs 4, 413-415
2. Chames, P., Van Regenmortel, M., Weiss, E., and Baty, D. (2009) Therapeutic antibodies. Successes, limitations and hopes for the future. Br. J. Pharmacol. 157, 220-233
3. Hey, T., Fiedler, E., Rudolph, R., and Fiedler, M. (2005) Artificial, nonantibody binding proteins for pharmaceutical and industrial applications. Trends Biotechnol. 23, 514-522 (Pubitemid 41317915)
4. Gebauer, M., and Skerra, A. (2009) Engineered protein scaffolds as next-generation antibody therapeutics. Curr. Opin. Chem. Biol. 13, 245-255
5. Weidle, U. H., Auer, J., Brinkmann, U., Georges, G., and Tiefenthaler, G. (2013) The emerging role of new protein scaffold-based agents for treatment of cancer. Cancer Genomics Proteomics 10, 155-168
6. Baum, R. P., Prasad, V., Müller, D., Schuchardt, C., Orlova, A., Wennborg, A., Tolmachev, V., and Feldwisch, J. (2010) Molecular imaging of Her2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J. Nucl. Med. 51, 892-897
7. Tolcher, A. W., Sweeney, C. J., Papadopoulos, K., Patnaik, A., Chiorean, E. G., Mita, A. C., Sankhala, K., Furfine, E., Gokemeijer, J., Iacono, L., Eaton, C., Silver, B. A., and Mita, M. (2011) Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. Clin. Cancer Res. 17, 363-371
8. Campochiaro, P. A., Channa, R., Berger, B. B., Heier, J. S., Brown, D. M., Fiedler, U., Hepp, J., and Stumpp, M. T. (2013) Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor. A Phase I/II study. Am. J. Ophthalmol. 155, 697-704
9. Vijay-Kumar, S., Bugg, C. E., and Cook, W. J. (1987) Structure of ubiquitin refined at 1.8 Å resolution. J. Mol. Biol. 194, 531-544
10. Jackson, S. E. (2006) Ubiquitin. A small protein folding paradigm. Org. Biomol. Chem. 4, 1845-1853
11. Hirsch, C., Gauss, R., Horn, S. C., Neuber, O., and Sommer, T. (2009) The ubiquitylation machinery of the endoplasmic reticulum. Nature 458, 453-460
12. Bergink, S., and Jentsch, S. (2009) Principles of ubiquitin and SUMO modifications in DNA repair. Nature 458, 461-467
13. Raiborg, C., and Stenmark, H. (2009) The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteins. Nature 458, 445-452
14. Majetschak, M. (2011) Extracellular ubiquitin. Immune modulator and endogenous opponent of damage-associated molecular pattern molecules. J. Leukoc. Biol. 89, 205-219
15. Takada, K., Nasu, H., Hibi, N., Tsukada, Y., Shibasaki, T., Fujise, K., Fujimuro, M., Sawada, H., Yokosawa, H., and Ohkawa, K. (1997) Serum concentrations of free ubiquitin and multiubiquitin chains. Clin. Chem. 43, 1188-1195 (Pubitemid 27297262)
16. Komander, D., and Rape, M. (2012) The ubiquitin code. Annu. Rev. Biochem. 81, 203-229
17. Saini, V., Staren, D. M., Ziarek, J. J., Nashaat, Z. N., Campbell, E. M., Volkman, B. F., Marchese, A., and Majetschak, M. (2011) The CXC chemokine receptor 4 ligands ubiquitin and stromal cell-derived factor-1α function through distinct receptor interactions. J. Biol. Chem. 286, 33466-33477
18. Saini, V., Marchese, A., Tang, W. J., and Majetschak, M. (2011) Structural determinants of ubiquitin-CXC chemokine receptor 4 interaction. J. Biol. Chem. 286, 44145-44152
19. Saini, V., Romero, J., Marchese, A., and Majetschak, M. (2010) Ubiquitin receptor binding and signaling in primary human leukocytes. Commun. Integr. Biol. 3, 608-610
20. Majetschak, M., Krehmeier, U., Bardenheuer, M., Denz, C., Quintel, M., Voggenreiter, G., and Obertacke, U. (2003) Extracellular ubiquitin inhibits the TNF-α response to endotoxin in peripheral blood mononuclear cells and regulates endotoxin hyporesponsiveness in critical illness. Blood 101, 1882-1890 (Pubitemid 36237589)
21. Baker, T. A., Romero, J., Bach, H. H., 4th, Strom, J. A., Gamelli, R. L., and Majetschak, M. (2012) Effects of exogenous ubiquitin in a polytrauma model with blunt chest trauma. Crit. Care. Med. 40, 2376-2384
22. Bach, H. H., 4th, Saini, V., Baker, T. A., Tripathi, A., Gamelli, R. L., and Majetschak, M. (2012) Initial assessment of the role of CXC chemokine receptor 4 after polytrauma. Mol. Med. 18, 1056-1066
23. Majetschak, M., Cohn, S. M., Obertacke, U., and Proctor, K. G. (2004) Therapeutic potential of exogenous ubiquitin during resuscitation from severe trauma. J. Trauma 56, 991-999; discussion 999-1000
24. Majetschak, M., Cohn, S. M., Nelson, J. A., Burton, E. H., Obertacke U., and Proctor, K. G. (2004) Effects of exogenous ubiquitin in lethal endotoxemia. Surgery 135, 536-543 (Pubitemid 38586528)
25. Schwarzbauer, J. E., Patel, R. S., Fonda, D., and Hynes, R. O. (1987) Multiple sites of alternative splicing of the rat fibronectin gene transcript. EMBO J. 6, 2573-2580
26. Menrad, A., and Menssen, H. D. (2005) ED-B fibronectin as a target for antibody-based cancer treatments. Expert Opin. Ther. Targets 9, 491-500 (Pubitemid 40883149)
27. Johdi, N. A., Harman, R., Sanjuan, I., Kousparou, C., Courtenay-Luck, N., and Deonarain M. P. (2013) Production and binding analyses of a humanised scFv against a cryptic epitope on tumour-associated fibronectin. Protein Expr. Purif. 88, 157-163
28. Grabulovski, D., Kaspar, M., and Neri, D. (2007) A novel, non-immunogenic Fyn SH3-derived binding protein with tumor vascular targeting properties. J. Biol. Chem. 282, 3196-3204 (Pubitemid 47084313)
29. Gebauer, M., Schiefner, A., Matschiner, G., and Skerra, A. (2013) Combinatorial design of an anticalin directed against the extra-domain b for the specific targeting of oncofetal fibronectin. J. Mol. Biol. 425, 780-802
30. Pini, A., Viti, F., Santucci, A., Carnemolla, B., Zardi, L., Neri, P., and Neri, D. (1998) Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J. Biol. Chem. 273, 21769-21776 (Pubitemid 28405353)
31. Demartis, S., Tarli, L., Borsi, L., Zardi, L., and Neri, D. (2001) Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin. Eur. J. Nucl. Med. 28, 534-539 (Pubitemid 32260922)
32. Borsi, L., Balza, E., Bestagno, M., Castellani, P., Carnemolla, B., Biro, A., Leprini, A., Sepulveda, J., Burrone, O., Neri, D., and Zardi, L. (2002) Selective targeting of tumoral vasculature. Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int. J. Cancer 102, 75-85
33. Ronca, R., Sozzani, S., Presta, M., and Alessi, P. (2009) Delivering cytokines at tumor site. The immunocytokine-conjugated anti-EDB-fibronectin antibody case. Immunobiology 214, 800-810
34. Sauer, S., Erba, P. A., Petrini, M., Menrad, A., Giovannoni, L., Grana, C., Hirsch, B., Zardi, L., Paganelli, G., Mariani, G., Neri, D., Dürkop, H., and Menssen, H. D. (2009) Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131IL19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 113, 2265-2274
35. Johannsen, M., Spitaleri, G., Curigliano, G., Roigas, J., Weikert, S., Kempkensteffen, C., Roemer, A., Kloeters, C., Rogalla, P., Pecher, G., Miller, K., Berndt, A., Kosmehl, H., Trachsel, E., Kaspar, M., Lovato, V., González-Iglesias, R., Giovannoni, L., Menssen, H. D., Neri, D., and de Braud, F. (2010) The tumour-targeting human L19-IL2 immunocytokine. Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur. J. Cancer 46, 2926-2935
36. Spitaleri, G., Berardi, R., Pierantoni, C., De Pas, T., Noberasco, C., Libbra, C., González-Iglesias, R., Giovannoni, L., Tasciotti, A., Neri, D., Menssen, H. D., and de Braud, F. (2013) Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours. J. Cancer Res. Clin. Oncol. 139, 447-455
37. Fiedler, M., Fiedler, U., and Rudolph, R. (August 30, 1980) Generation of artificial binding proteins on the basis of ubiquitin proteins. International Patent Application WO/2004/106368
38. Paschke, M., and Höhne, W. (2005) A twin-arginine translocation (Tat)-mediated phage display system. Gene 350, 79-88
39. Ebersbach, H., Fiedler, E., Scheuermann, T., Fiedler, M., Stubbs, M. T., Reimann, C., Proetzel, G., Rudolph, R., and Fiedler, U. (2007) Affilin-novel binding molecules based on human γ-B-crystallin, an all β-sheet protein. J. Mol. Biol. 372, 172-185 (Pubitemid 47223227)
40. Zahnd, C., Amstutz, P., and Plückthun, A. (2007) Ribosome display. Selecting and evolving proteins in vitro that specifically bind to a target. Nat. Methods 4, 269-279 (Pubitemid 46358879)
41. Borsi, L., Balza, E., Carnemolla, B., Sassi, F., Castellani, P., Berndt, A., Kosmehl, H., Biro, A., Siri, A., Orecchia, P., Grassi, J., Neri, D., and Zardi, L. (2003) Selective targeted delivery of TNFα to tumor blood vessels. Blood 102, 4384-4392 (Pubitemid 37494099)
42. Bosse-Doenecke, E., Weininger, U., Gopalswamy, M., Balbach, J., Knudsen, S. M., and Rudolph, R. (2008) High yield production of recombinant native and modified peptides exemplified by ligands for G-protein coupled receptors. Protein Expr. Purif. 58, 114-121
43. Mossessova, E., and Lima, C. D. (2000) Ulp1-SUMO crystal structure and genetic analysis reveal conserved interactions and a regulatory element essential for cell growth in yeast. Mol. Cell 5, 865-876
44. Fee, C. J. (2007) Size comparison between proteins PEGylated with branched and linear poly(ethylene glycol) molecules. Biotechnol. Bioeng. 98, 725-731
45. Saha, G. B., Whitten, J., and Go, R. T. (1989) Conditions of radioiodination with iodogen as oxidizing agent. Int. J. Rad. Appl. Instrum. B 16, 431-433 (Pubitemid 19167975)
46. Garg, P. K., Alston, K. L., Welsh, P. C., and Zalutsky, M. R. (1996) Enhanced binding and inertness to dehalogenation of α-melanotropic peptides labeled using N-succinimidyl 3-iodobenzoate. Bioconjug. Chem. 7, 233-239 (Pubitemid 126639652)
47. Lindmo, T., Boven, E., Cuttitta, F., Fedorko, J., and Bunn, P. A., Jr. (1984) Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Methods 72, 77-89 (Pubitemid 14091996)
48. Khorasanizadeh, S., Peters, I. D., Butt, T. R., and Roder, H. (1993) Folding and stability of a tryptophan-containing mutant of ubiquitin. Biochemistry 32, 7054-7063 (Pubitemid 23221641)
49. Catic, A., Misaghi, S., Korbel, G. A., and Ploegh, H. L. (2007) ElaD, a Deubiquitinating protease expressed by E. coli. PLoS One 2, e381
50. Hoffmann, A., Kovermann, M., Lilie, H., Fiedler, M., Balbach, J., Rudolph, R., and Pfeifer, S. (2012) New binding mode to TNF-α revealed by ubiquitin-based artificial binding protein. PLoS One 7, e31298
51. 48-linked tetraubiquitin at neutral pH. Mol. Biol. 367, 204-211
52. 63-linked and linear polyubiquitin chains. EMBO Rep. 10, 466-473
53. Boersma, Y. L., and Plückthun, A. (2011) DARPins and other repeat protein scaffolds. Advances in engineering and applications. Curr. Opin. Biotechnol. 22, 849-857
54. Tojo, A., and Kinugasa, S. (2012) Mechanisms of glomerular albumin filtration and tubular reabsorption. Int. J. Nephrol. 2012, 481520
55. Earle, S. A., Proctor, K. G., Patel, M. B., and Majetschak, M. (2005) Ubiquitin reduces fluid shifts after traumatic brain injury. Surgery 138, 431-438 (Pubitemid 41415569)
56. Kontermann, R. E. (2011) Strategies for extended serum half-life of protein therapeutics. Curr. Opin. Biotechnol. 22, 868-876
57. Vauquelin, G. (2010) Rebinding. Or why drugs may act longer in vivo than expected from their in vitro target residence time. Expert Opin. Drug Discov. 5, 927-941
58. Kuo, T. T., and Aveson, V. G. (2011) Neonatal Fc receptor and IgG-based therapeutics. mAbs 3, 422-430
59. Wang, Y. M., Sloey, B., Wong, T., Khandelwal, P., Melara, R., and Sun, Y. N. (2011) Investigation of the pharmacokinetics of romiplostim in rodents with a focus on the clearance mechanism. Pharm. Res. 28, 1931-1938
60. Andersen, J. T., Daba, M. B., Berntzen, G., Michaelsen, T. E., and Sandlie, I. (2010) Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding. J. Biol. Chem. 285, 4826-4836
61. Chaudhury, C., Brooks, C. L., Carter, D. C., Robinson, J. M., and Anderson, C. L. (2006) Albumin binding to FcRn. Distinct from the FcRn-IgG interaction. Biochemistry 45, 4983-4990
62. Hoppmann, S., Miao, Z., Liu, S., Liu, H., Ren, G., Bao, A., and Cheng, Z. (2011) Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting. Bioconjug. Chem. 22, 413-421
63. Veronese, F. M., and Pasut, G. (2005) PEGylation, successful approach to drug delivery. Drug Discov. Today 10, 1451-1458 (Pubitemid 41483874)
64. Kubetzko, S., Sarkar, C. A., and Plückthun, A. (2005) Protein PEGylation decreases observed target association rates via a dual blocking mechanism. Mol. Pharmacol. 68, 1439-1454 (Pubitemid 41540000)
65. Dhalluin, C., Ross, A., Huber, W., Gerber, P., Brugger, D., Gsell, B., and Senn, H. (2005) Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-α2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug. Chem. 16, 518-527 (Pubitemid 40696042)